EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report of entrectinib associated fulminant myocarditis

Gohar Rundhawa, Murtaza Ali iD, Ron Jacob, Edmond Obeng-Gyimah, Michael N Vranian

European Heart Journal - Case Reports · 24.12.2024 · 9 (1)

DOI: 10.1093/ehjcr/ytae650 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Heart Journal - Case Reports, online erschienen am 10.12.2024. Verfasst von Gohar Rundhawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, York Hospital, WellSpan Health, 30 Monument Rd, York, PA 17403, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ROS1 tyrosine kinase inhibitors are one of the primary immunotherapies for ROS1 fusion-positive cancers. Tyrosine kinase inhibitors have markedly improved outcomes for advanced cancers previously with poor prognosis. Entrectinib is an example of an ROS1 inhibitor that can be used for lung adenocarcinoma. There are numerous adverse effects with rare cardiac side effects reported, such as heart failure and myocarditis. Case summary A 27-year-old male being treated for lung adenocarcinoma who presented new congestive heart failure 2 weeks after starting Entrectinib. He developed refractory ventricular tachycardia, cardiogenic shock with an endomyocardial biopsy that showed active lymphohistiocytic myocarditis. With antiarrhythmic therapy, heavy sedation, mechanical circulatory support, and high-dose steroids, the patient had complete resolution of symptoms and return to baseline status.

Discussion

This is a rare case with a severe complication after starting Entrectinib for lung adenocarcinoma. In the literature, this is the first case of its kind presenting with myocarditis and severe heart failure after treatment with Entrectinib. This case highlights not only using cardiac imaging, and biopsy to help guide the diagnosis, but also describe the appropriate management.

Schlagwörter

Stichwörter der Autor:innen

CardiotoxicityCase reportECMOEntrectinibFulminant myocarditisVentricular tachycardia

Autor:innen und Institutionen

  • Department of Internal Medicine, York Hospital, WellSpan Health, 30 Monument Rd, York, PA 17403, USA.
  • Department of Cardiology, York Hospital, WellSpan Health, 30 Monument Rd, York, PA 17403, USA.

ORCID-Profile: Murtaza Ali

Zitieren

APA

Rundhawa, G., Ali, M., Jacob, R., Obeng-Gyimah, E., & Vranian, M. N. (2024). Case report of entrectinib associated fulminant myocarditis. European Heart Journal - Case Reports, 9(1). https://doi.org/10.1093/ehjcr/ytae650

Vancouver

Rundhawa G, Ali M, Jacob R, Obeng-Gyimah E, Vranian MN. Case report of entrectinib associated fulminant myocarditis. European Heart Journal - Case Reports. 2024;9(1). doi:10.1093/ehjcr/ytae650

BibTeX
@article{Rundhawa2024,
  author = {Rundhawa, Gohar and Ali, Murtaza and Jacob, Ron and Obeng-Gyimah, Edmond and Vranian, Michael N},
  title = {Case report of entrectinib associated fulminant myocarditis},
  journal = {European Heart Journal - Case Reports},
  year = {2024},
  volume = {9},
  number = {1},
  doi = {10.1093/ehjcr/ytae650}
}
Kostenlos starten →